Rianne L Seefat - JoVE Visualize

Showing results (1-10 of 3) with videos related to

Pageof 1

Sort By:

Health Policy (Amsterdam, Netherlands)|May 26, 2026

Coverage with evidence development programs: a scoping review on characteristics and patient accessJoost G E Verbeek, Rianne L Seefat, Erica A Wilthagen, et al.

The Lancet. Haematology|November 3, 2023

R-CODOX-M/R-IVAC versus DA-EPOCH-R in patients with newly diagnosed Burkitt lymphoma (HOVON/SAKK): final results of a multicentre, phase 3, open-label, randomised trialMartine E D Chamuleau, Frank Stenner, Dana A Chitu, et al.

The Lancet. Oncology|June 29, 2026

Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trialRianne L Seefat, Sonja B Vliek, Vincent M T de Jong, et al.

Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:

Pageof 1

Health Policy (Amsterdam, Netherlands)|May 26, 2026

Coverage with evidence development programs: a scoping review on characteristics and patient accessJoost G E Verbeek, Rianne L Seefat, Erica A Wilthagen, et al.

The Lancet. Haematology|November 3, 2023

R-CODOX-M/R-IVAC versus DA-EPOCH-R in patients with newly diagnosed Burkitt lymphoma (HOVON/SAKK): final results of a multicentre, phase 3, open-label, randomised trialMartine E D Chamuleau, Frank Stenner, Dana A Chitu, et al.

The Lancet. Oncology|June 29, 2026

Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trialRianne L Seefat, Sonja B Vliek, Vincent M T de Jong, et al.

Pageof 1